A Double-Masked, Randomized, Controlled, Multiple-Dose Study to Evaluate the Efficacy, Safety and Tolerability of QR-421a in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene With Early to Moderate Vision Loss
Latest Information Update: 09 Aug 2024
At a glance
- Drugs Ultevursen (Primary)
- Indications Retinitis pigmentosa; Usher syndromes
- Focus Registrational; Therapeutic Use
- Acronyms Celeste
- Sponsors ProQR Therapeutics
- 28 Dec 2022 Status changed from active, no longer recruiting to discontinued as per business decision.
- 07 Jul 2022 This trial has been completed in Denmark, according to European Clinical Trials Database record.
- 16 Jun 2022 This trial has been completed in France according to European Clinical Trials Database record.